Pharnext Logo

Pharnext

ALPHA | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0011191287 (+4 more)
LEI:
969500KJGF9ZUYXSMJ27
Country:
France
Address:
9 RUE DES FILLES SAINT-THOMAS, 75002 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Our company Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs. Our drug Candidates Two drug candidates are currently in clinical development: PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for Alzheimer’s disease. Both of our lead assets originated from the Pleotherapy R&D approach.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-27 13:00
Legal Proceedings Report
Ouverture d'une procédure de liquidation judiciaire
French 194.1 KB
2024-08-01 18:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 189.9 KB
2024-07-18 18:00
Capital/Financing Update
Point concernant l'accord de financement en obligations convertibles accordé pa…
French 194.2 KB
2024-07-15 18:00
Legal Proceedings Report
Demande d'ouverture d'une procédure de liquidation judiciaire
French 193.2 KB
2024-07-10 08:00
Capital/Financing Update
Pharnext fait un point sur sa situation financière
French 191.6 KB
2024-07-04 20:00
Legal Proceedings Report
Pharnext annonce la résiliation du contrat de financement accordé par Néovacs
French 232.3 KB
2024-07-03 08:00
Capital/Financing Update
Pharnext fait un point sur les conséquences de sa situation stratégique et fina…
French 208.2 KB
2024-07-01 18:30
Share Issue/Capital Change
Information relative au nombre total de droits de vote et d'actions composant l…
French 185.7 KB
2024-06-28 08:00
Legal Proceedings Report
Pharnext fait un point d'étape sur les dernières avancées majeures d'un point d…
French 209.3 KB
2024-06-18 18:30
AGM Information
Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 jui…
French 194.9 KB
2024-06-05 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 181.3 KB
2024-05-29 18:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 190.9 KB
2024-05-07 19:10
Share Issue/Capital Change
Ajustement de la valeur nominale
French 190.6 KB
2024-05-06 18:00
Pre-Annual General Meeting Information
Pharnext convoque ses actionnaires en assemblée générale le 10 juin 2024
French 194.7 KB
2024-05-02 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 195.4 KB

Automate Your Workflow. Get a real-time feed of all Pharnext filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharnext

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharnext via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.
United Kingdom
ANAN
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America
ANAB
Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.
Türkiye
ANGEN
ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.